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Candidate gene resequencing to identify
rare, pedigree-specific variants influencing
healthy aging phenotypes in the long life
family study
Todd E. Druley1,2, Lihua Wang1,3, Shiow J. Lin1,3, Joseph H. Lee4,5,6, Qunyuan Zhang1,3, E. Warwick Daw1,3,
Haley J. Abel1,3, Sara E. Chasnoff1,2, Enrique I. Ramos1,2, Benjamin T. Levinson1,2, Bharat Thyagarajan7,
Anne B. Newman8, Kaare Christensen9, Richard Mayeux10 and Michael A. Province1,3*

Abstract
Background: The Long Life Family Study (LLFS) is an international study to identify the genetic components of
various healthy aging phenotypes. We hypothesized that pedigree-specific rare variants at longevity-associated
genes could have a similar functional impact on healthy phenotypes.
Methods: We performed custom hybridization capture sequencing to identify the functional variants in 464
candidate genes for longevity or the major diseases of aging in 615 pedigrees (4,953 individuals) from the LLFS,
using a multiplexed, custom hybridization capture. Variants were analyzed individually or as a group across an
entire gene for association to aging phenotypes using family based tests.
Results: We found significant associations to three genes and nine single variants. Most notably, we found a novel
variant significantly associated with exceptional survival in the 3’ UTR OBFC1 in 13 individuals from six pedigrees.
OBFC1 (chromosome 10) is involved in telomere maintenance, and falls within a linkage peak recently reported
from an analysis of telomere length in LLFS families. Two different algorithms for single gene associations identified
three genes with an enrichment of variation that was significantly associated with three phenotypes (GSK3B with
the Healthy Aging Index, NOTCH1 with diastolic blood pressure and TP53 with serum HDL).
Conclusions: Sequencing analysis of family-based associations for age-related phenotypes can identify rare or
novel variants.
Keywords: Genomics, Aging, Genetics, Geriatrics, Pedigrees, Family, Sequencing

Background
According to United Nations World Population Prospects
2012 revision (http://esa.un.org/unpd/wpp/Documenta
tion/pdf/WPP2012_HIGHLIGHTS.pdf), the worldwide
average human lifespan was 71 years (68.5 years for males
and 73.5 years for females) over the period 2010–2013. At
least 25 % of human lifespan is dictated by genetic factors,
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most of which is unknown [1]. Currently, most human
longevity and healthy aging related variants identified
through genome wide association study (GWAS) are either intergenic or intronic with weak effects, and there is
little characterization of coding variants that may influence human lifespan. For instance, common variants in
multiple genes such as apolipoprotein E (APOE) [2–5],
Forkhead Box O1 (FOXO1) [6], Forkhead Box O3
(FOXO3) [7], Insulin-Like Growth Factor 1 Receptor
(IGF-1R) [6, 8] and Translocase of Outer Mitochondrial
Membrane 40 Homolog (TOMM40) [9] have all been associated with human lifespan. However, lifespan is a highly
complex trait and healthy aging is controlled and
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influenced by variety of environmental factors and individual phenotypes [10]. Leukocyte telomere length, Body
Mass Index (BMI), blood pressure, serum lipids, blood
glucose, cognitive function, onset of type 2 diabetes,
heart disease, cancer, and stroke are a few phenotypes
associated with aging, and we hypothesized that
pedigree-specific coding variants associated with these
traits would identify additional genes or pathways important for regulating human lifespan. While noncoding variants may have significant gene or epigenetic
regulatory effects, exonic variants would be expected to
exert larger effects on gene function and might therefore explain a larger fraction of the variance in these
complex aging phenotypes.
Thus, we expect families clustered for long-lived
healthy members [11, 12] to be enriched for genetic
variants that will promote healthy and/or prolonged
aging. To identify new, rare, heritable variants that are
associated with multiple healthy aging phenotypes, we
performed custom hybridization capture sequencing
of 464 healthy aging related candidate genes in Phase
1 of the Long Life Family Study (LLFS). We then performed association analyses of both rare (<1 % minor
allele frequency) and common variants against multiple aging-related phenotypes including survival,
leukocyte telomere length, healthy aging index [13],
BMI, blood pressure, blood lipid levels, blood glucose
level, cognitive function, onset of type 2 diabetes,
heart disease, cancer, and stroke.

Methods
Subjects

The LLFS [11], a multi-center family-based cohort
study, enrolled 4,953 individuals from 539 families
clustered for exceptional survival to identify environmental and genetic factors that account for the long
healthy lives in these families. Phase 1 of the LLFS was
conducted between 2006 and 2009. All participants
provided written informed consent prior to inclusion
in the study. The four recruitment centers include
Boston University Medical Center, Columbia University Medical Center, University of Pittsburgh, and University of Southern Denmark. Using the Family
Longevity Selection Score (FLoSS) [14], a score generated according to birth-year cohort survival probabilities of the proband and siblings, probands and their
families with FLoSS score of 7 or higher, at least one
living sibling, and at least one living offspring (minimum family size of 3), who were able to give informed
consent and willing to participate were recruited. The
spouses were enrolled as controls for this study. The
characteristics of the LLFS population by generation
and by gender are listed in Additional file 1: Table S1
and S2, respectively.
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Phenotype measurements

In this study, human lifespan and phenotypic traits related to healthy aging including survival, leukocyte telomere length, BMI, blood pressure, blood lipid levels,
blood glucose and insulin levels, cognitive function,
healthy aging index, as well as the ages of onset of
stroke, coronary heart disease, congestive heart failure,
cancer, and type 2 diabetes mellitus, were investigated.
Survival and mortality-weighted healthy aging index

The lifespan in LLFS was estimated as the duration of
survival free of death from any cause or from any one of
a specified list of diseases including cardiovascular disease, congestive heart failure, cancer, stroke, and Type 2
diabetes. The LLFS proband generation, including probands and full and half siblings (n = 810), was used for
identifying variants related with survival.
Healthy aging was established by the lack of disease
and clinical test values indicating normal function of
various biological systems. To increase the probability
of identifying healthy aging-related genetic variants,
which might influence one or more components of
these biological systems, Sanders et al. proposed the
Healthy Aging Index (HAI) as a subphenotype of longevity [13]. Using approximate age-adjusted tertiles for
systolic blood pressure, pulmonary vital capacity, creatinine, fasting glucose, and Modified Mini-Mental Status Examination score, each individual is scored 0, 1, or
2 for each trait. The HAI is then calculated from the
sum of these scores in a range from 0 (healthy) to 10
(unhealthy). The mortality-weighted HAI is generated
from the sum of the mortality-weighted scores of the
five components listed above. The weights are based on
the regression coefficients from the Cox proportional
hazards model for the effect of each component on survival and are 0.17085 for systolic blood pressure,
0.38386 for forced vital capacity, 0.42873 for MMSE
points, 0.13397 for serum creatinine, and 0.23880 for
serum fasting glucose.
Glycated hemoglobin (HbA1c), Blood Glucose and Insulin
Levels, Leukocyte Telomere Length, Blood Lipid Levels
Including Total Cholesterol, HDL Cholesterol, LDL
Cholesterol and Triglyceride, BMI, Blood Pressure,
Cognitive Function, Stroke, Coronary Heart Disease,
Congestive Heart Failure, Cancer, Type 2 Diabetes

We looked for any possible association between our candidate genes related to healthy aging and various aging
phenotypes including HbA1c, blood glucose and insulin
levels, leukocyte telomere length, blood lipid levels including total cholesterol, HDL cholesterol, LDL cholesterol and triglyceride, BMI, blood pressure, cognitive
function, stroke, coronary heart disease, congestive heart
failure, cancer, and type 2 diabetes.
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As described previously [15], blood samples were collected between 2006 and 2009, and HbA1c was measured
using identical ion exchange-based high performance liquid
chromatography with the Tosoh 2.2 Plus and after 2007
with the Tosch G7 Glycohemoglobin Analyzer (Tosoh
Medics, San Francisco, CA 94080) at the Advanced
Research and Diagnostics Laboratory, University of
Minnesota. Fasting glucose was measured after an 8-h
fast in serum by the Roche hexokinase method (Roche
Diagnostics, Indianapolis, IN 46250) on a Roche Modular
P Chemistry Analyzer (Roche Diagnostics Corporation).
Fasting insulin was measured after an 8-h fast in serum
on a Roche Elecsys 2010 Analyzer (Roche Diagnostics
Corporation) using a sandwich immunoassay method
(Roche Diagnostics, Indianapolis, IN 46250). Assays of
average leukocyte telomere length were described by Lee
et al. [16]. Briefly, Telomeres (T) and beta-globin control
(S) were amplified using real-time PCR of 95 °C for
10 min denaturation, 34 cycles of 95 °C for 15 s and 55 °C
for 120 s performed on the CFX384 thermocycler (BioRad,
Richmond, CA). The leukocyte telomere length was
calculated from T/S ratio using the linear regression formula of bp = (1,585 ∗ T/S ratio) + 3582. Fasting total cholesterol was measured after an 8-h fast in serum using a
cholesterol oxidase method (Roche Diagnostics, Indianapolis,
IN 46250) on a Roche Modular P Chemistry Analyzer.
Fasting HDL-cholesterol was measured after an 8-h fast
directly in serum using the Roche HDL-Cholesterol 3rd
generation direct method (Roche Diagnostics, Indianapolis,
IN 46250) on a Roche Modular P Chemistry Analyzer.
Fasting triglycerides were measured after an 8-h fast in
serum using Triglyceride GB reagent (Roche Diagnostics, Indianapolis, IN 46250) on a Roche Modular P
Chemistry Analyzer. LDL-cholesterol was calculated by
the Friedewald equation using the measured results for
total cholesterol, HDL-cholesterol, and triglycerides.
This equation (LDL-cholesterol = total cholesterol –
HDL – (triglycerides/5)) can be used to calculate LDLcholesterol when triglycerides are less than 400 mg/dL.
The corrected values for triglyceride and LDL cholesterol was calculated for individuals taking lipid lowering medications [17]. BMI was calculated as weight
(kg)/height (m)2. Sitting systolic and diastolic blood
pressure was obtained by the average of three measures
using an automated blood pressure machine (BP-tru
BPM 300, VMS MedTech, Coquitlam, Canada). Pulse
Pressure was calculated as systolic blood pressure
minus diastolic blood pressure. These results were corrected for individuals taking blood pressure modifying
medication as previously published [18]. General cognitive function including arithmetic, memory, and orientation was assessed using the mini-mental state
examination (MMSE) or Folstein test [19]. Stroke or
cerebrovascular accident includes self-reported stroke,
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transient ischemic attack (TIA), or mini-stroke. Coronary
heart disease was defined as self-reported myocardial infarction, heart attack, coronary angioplasty, or coronary
artery bypass grafting. Heart failure or congestive heart
failure and cancer (including breast cancer, colon or rectal
cancer, esophageal cancer, leukemia or lymphoma, lung
cancer, pancreatic cancer, prostate cancer, etc.) were selfreported. Type 2 diabetes was defined as use of diabetes
medications or fasting glucose ≥ 126 mg/dl.
Genome-wide SNP array genotyping

Illumina Human Omni 2.5 v1 was used to perform
whole genome SNP genotyping on each study participant
by CIDR (www.cidr.jhmi.edu), and the resulting data
has been submitted to dbGaP under accession number
phs000397.v1.p1. Genome-wide SNP variants within targeted sequenced regions were used as controls for sequencing accuracy as described below.
Pooled sequencing and indexed custom library
preparation

We have previously published the entire protocol for
custom hybridization capture of multiplexed, indexed
next generation sequencing [20, 27]. Briefly, customized
adapter, blocker, pre- and post-hybridization PCR amplification primers and all index sequences used are listed
in Additional file 1: Table S5 of the same report. We
performed pooled capture of 464 candidate genes
(Additional file 1: Table S3) selected collectively by the
LLFS investigators due to their published association
with age-related phenotypes. Candidate gene resequencing was performed from individually indexed DNA
samples from LLFS participants [https://longlifefamilystudy.wustl.edu/LLFS/Home.html]. The bait set was created using the Agilent eArray online tool [https://
earray.chem.agilent.com/earray/] for the Agilent SureSelect Custom DNA Capture [http://www.genomics.agilent.com] using 2X tiling, an exon-centered layout
strategy, and eliminating probes that overlap standard
repeat masked regions by 20 or more bases. In total,
there were 2,500,709 bases (2.5 Mb) covered by baits in
6,966 distinct intervals.
Sequencing

Sequencing was performed in the Genome Technology
Access Center at Washington University using the HiSeq
2000 platform, generating 101 bp paired-end reads.
GWA and sequencing information for the LLFS participants is available in dbGaP using accession number
phs000397.v1.p1.
Sequencing alignment, variant calling and filtering

Sequencing analysis for indexed captures of all LLFS
participants followed previously reported methods (27;
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section entitled “Pooled indexed custom capture data
analysis” for more details). Briefly, raw sequence data
was aligned against the human genome (hg19/NCBI
37.0) using Novoalign (Novocraft, Inc.) and, from
aligned reads, variants were called using samtools-0.1.18
mpileup at only the 2.5 Mb of target sequence within
our custom hybridization array.
The thresholds used for filtering called variants from sequencing data were determined by comparing common
base positions shared with existing GWA data. For genelevel burden tests, variants were filtered for coverage <5fold, quality score <45, call rate < 60 %, MAF > 0.01, Mendel
errors, and nonfunctional variants. Single variants were filtered for coverage <5-fold, quality score <45, call rate <
60 %, and Mendel errors. For rare variants (<2 % minor
allele frequency), these thresholds provided a sensitivity
of ≥94.9 % and specificity of ≥99.9 % [27]. Mendel error
cutoffs were implemented as follows: MAF = 0 to <0.01
for >2 pedigrees with the Mendel error; MAF = 0.01 to <0.05
for ≥7 pedigrees; MAF = 0.05 to <0.1 for ≥12 pedigrees;
MAF = 0.1 to <0.2 for ≥26 pedigrees; MAF = 0.2 to <0.3
for ≥30 pedigrees; MAF = 0.3 to <0.4 for ≥32 pedigrees;
MAF = 0.4 to <0.51 for ≥38 pedigrees.
Statistical analyses
Trait exceptionality scores for survival, BMI, blood pressure,
blood lipid levels, blood glucose level, blood insulin level,
cognitive function, type 2 diabetes, heart disease, cancer,
and stroke

The LLFS cohort is enriched with longer-lived and
healthier individuals than the general population, as well
as the Framingham Heart Study. To account for this difference and increase our statistical power for detecting
sequence variants associated with aging-related phenotypes, such as survival, BMI, blood pressure, blood lipid
levels, blood glucose level, blood insulin level, cognitive
function, type 2 diabetes, heart disease, cancer, and
stroke are transformed to “trait exceptionality scores”.
Higher trait exceptionality scores indicate that, for a
given trait, an individual is significantly different from
the reference population for the same trait, resulting in
longer individual survival and/or better health. Using
sex- and birth-year specific cohort life tables from the
2012 trustees report of the United States Social Security
Administration, the trait exceptionality scores for survival were calculated for the oldest (proband) generation
in LLFS, along with any blood relatives within the same
generation regardless of age. These calculations are conditional on survival to age 40 and were determined as
the negative logarithm of the probability of survival beyond age at last contact. Trait exceptionality scores for
BMI, blood pressure, blood lipid levels, blood glucose
level, blood insulin level, and cognitive function were
also calculated as the negative logarithm of the
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probability of the trait score compared to the age/sex/
birth-cohort matched in the Framingham Heart Study.
Trait exceptionality scores for type 2 diabetes, heart disease, cancer, and stroke were calculated as the negative
logarithm of the probability of the onset age of the disease, and compared to the distribution of the age of onset for each trait in the Framingham Heart Study. There
are two additional components to the HAI, which are
pulmonary vital capacity and serum creatinine. However,
these were not available in Framingham Heart Study and
were not included in our analyses.
Phenotype transformation and covariates adjustment

To increase the power and reduce the confounder effects of our analyses, we performed the following covariates adjustment and transformation. HbA1c was adjusted
for age, age2, age3, field center and the top twenty principal components (PCs); the standardized residuals from a
stepwise covariate adjustment were used as final phenotype for the following association analyses. The
leukocyte telomere length was transformed using an inverse normal function. This transformed trait was adjusted for covariates age, sex, education, field center,
smoking, alcohol consumption, marital status, history of
heart disease, and twenty PCs (PC8 was the only significant PC associated with leukocyte telomere length in the
multivariate polygenic model). Mortality weighted
healthy aging index were adjusted for age, sex, and 10
PCs and the residuals were used in the following analyses. The residuals of trait exceptionality scores adjusted
for field centers and 20 PCs were used in the following
analyses.
Single variant association testing

Family relatedness was estimated based on pedigree
structure using the “kinship” R package. Accounting for
this relatedness within families as random effects, the
additive genetic fixed effects of SNPs were analyzed
using the linear mixed effects model implemented in the
“lmekin” R packages [21, 22]. Q-Q plots for the phenotypes analyzed are shown in Additional file 1: Figure S1
and demonstrate that, compared to genomic control
(calculated as median of observed p value / median of
expected p value to avoid estimation bias), each is within
0.578–1.09 using this approach. Thus, the type I error
rate is low in this study.
Rare variant testing across genes

Currently un-weighted sum score (UWSS) [23],
weighted sum score (WSS) [24], P-value Weighted Sum
Test (PWST) method [25] and family based sequence
kernel association test (famSKAT) [26] are commonly
used for estimating the effects of rare variants. Because
the PWST and famSKAT are likely to have greater power
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to detect rare causal variants, we applied these two algorithms to assess the influence of called rare variants.
This was necessary since standard association tests of individual rare variants (MAF < 0.01) are underpowered
unless sample sizes or effect sizes are very large, functional variants within the same gene based on bioinformatics annotation by ANNOVAR [27] were analyzed
together in this study. For each group of variants, UWSS
was calculated as the total number of variant alleles carried by a subject. The weight was calculated based on allele frequency in controls and WSS was calculated as the
weighted sum of minor alleles over a group of variants.
The UWSS or WSS score was treated as a single predictor variable (X) and fit into a linear model. The kinship matrix was incorporated into the linear models to
adjust for familial relatedness between subjects. Parameters in each model were estimated by the maximum likelihood algorithm and tested by the Wald test. Rather
than using a fixed weight, the PWST method adaptively
calculates the weights for individual variants from the
observed genotype and phenotype data and then performs a permutation procedure for family data to avoid
false positive inflation due to the over fitting of the adaptive score WSS.

Results
Sample characteristics
Phenotype

Our results included 4,217 LLFS subjects (mean of age
70.56 for men and 70.05 for women) with complete
phenotypic and genotypic information. Individuals with
inadequate GWA or sequencing coverage were excluded.
The study participants tend to have healthier profiles
compared with other cohorts of adults. For these individuals, the mean score of healthy aging index (3.64 in
men and women) and mortality weighted healthy aging
index (3.24 in men and 3.03 in women) are low. The
average age of the LLFS probands and their relatives
(95.8 in men and 99.4 in women) is much higher than
the cohort life expectancy of US and Danish (an LLFS
study site) early 20th century birth cohorts (60–70 years)
and the current life expectancy in both populations
(~80 years).
Sequencing results

To reduce false positive variant calls, stringent filtering
of raw sequence data was employed and is described in
Table 1. After filtering, 30,112 variants within 439 genes
were identified with an average coverage of 47-fold,
quality score of 175 and call rate of 0.97. As shown in
Fig. 1, 37.4 % (11,261) of all called variants fell within
coding regions with 22.4 % (6,745) being either missense
(non-synonymous SNV) or nonsense (stop-gain and
stop-loss) variants; 50.7 % (15,281) fell within regulatory
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Table 1 Filter Applied in LLFS sequence data
Among 464 Candidate genes, 448 genes with 48,918 variants
sequenced
Filter 1: ≥ 5x coverage

47 ± 36

Filter 2: ≥ 45 quality score

175 ± 53

Filter 3: ≥ 60 % call rate

97 % ± 7 %

Filter 4: Mendel Errors

MAF dependent

439 genes with 30,112 variants analyzed

5’ or 3’ untranslated regions (UTR5 or UTR3, respectively). The majority of variants (59.8 %) were found
within a single LLFS family (Additional file 1: Table S4)
and (88.74 %, n = 26,723) were rare, occurring at <1 % in
the general population, and 12,303 (46.04 %) were singletons (Additional file 1: Table S5).
Single variant analyses

Because there are correlations between the target phenotypes, the likelihood of a single variant having a functional effect on a given phenotype was Bonferroni
corrected by dividing 0.05 by the total number of variants queried without accounting for the number of analyzed phenotypes. This resulted in p-values of 7.56x10−6
for survival and cancer and 1.47x10−5 for HDL, LDL and
triglycerides. We first attempted to determine if any single variant identified by sequencing was significantly associated with survival. We identified a novel regulatory
variant in the 3’ UTR of Oligonucleotide/Oligosaccharide-Binding Fold Containing 1, located on chromosome
10q24.33 (OBFC1; see Table 2) found in 13 individuals
from six pedigrees (Additional file 1: Table S6), which
was significantly associated (p = 6.18x10−7) with trait exceptionality for survival in long lived families. Intronic
variants of OBFC1 genotyped by Illumina array were
also queried, and two rare variants (rs79250842 in 11 individuals from 5 pedigrees and rs77987791 in 5 individuals from 1 pedigree) were also found to have a
significant association with survival (Fig. 2). OBFC1 is
involved in telomere maintenance and falls within a recently reported LLFS family-based association peak for
telomere length on chromosome 10 as shown in Fig. 2
[16]. This observation is supported by the association of
the same OBFC1 intronic variant (rs77987791) with
telomere length (p = 0.038). Interestingly, one long-lived
pedigree (pedID 25609942) with 14 family members was
clustered for all three rare variants in seven family members, which suggests that multiple rare variants within
OBFC1 might contribute to longer lifespan. The comparison of “survival” to OBFC1 genotype is shown in
Additional file 1: Figure S2A.
Linear mixed model based single variant testing is not
a stable method for rare variants with <10 minor allele
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Fig. 1 The distribution of sequenced variants within different genomic region

copies [28], which is strengthened by our pedigree-based
structure. While the effect of any single variant may be
slight, we found a significant association with survival
for 23 different variants in 23 healthy aging candidate
genes (Table 3). Among these 23 variants, only four have
been described in dbSNP. Eight of these genes (in bold)
have published reports linking them to longer lifespan
[9, 29–34]. These variants clustered in two families with
longer survival (Fig. 3), suggesting that the aggregation
of multiple variants in these genes may have a larger effect on survival. One subject who survived to age 110
carried 15 of these variants, and another surviving to age
101 years carries 9 of these variants. None of the variants were carried by spousal controls.

Among the 439 candidate genes, 160 are well-known
human longevity related genes based on LongevityMap
(http://genomics.senescence.info/longevity/) [35] and A
Catalog of Published Genome-Wide Association Studies
(http:/www.genome.gov/gwastudies/). When considering
survival and any single variant with a p-value of <0.05
and more than 10 allelic copies in the LLFS cohort, we
replicated 76 variants within these 160 genes (Additional
file 1: Table S7), which supports the validity of our analysis model. Four variants within FOXO3, a well-known
longevity related gene [36–39], were replicated for an association (p < 0.05) with survival.
We found associations with phenotypes other than survival. One candidate gene, IGF1R (Insulin-Like Growth

Table 2 Significant results of single variant testing for variants with more than 10 copies. Nine single variants with at least 10 allelic
copies were identified within five phenotypes. There were 6,613 variants analyzed across 426 genes for survival and cancer and
3,389 variants analyzed across 408 genes for HDL, LDL and triglycerides
Phenotype (TE Score)

chr

Position (hg19)

Survival

10

105642272

Cancer

15

99501295

HDL Cholesterol

16

57005301

LDL Cholesterol

Triglyceride

rsID

rs1532625

gene

Function

Ref

Variant

MAF

N

SE

P-value

OBFC1

UTR3

C

G

0.002

810

Beta
3.58

0.71

6.2E-7

IGF1R

UTR3

A

G

0.007

4210

0.58

0.13

3.7E-6

CETP

intron

T

C

0.38

3053

0.19

0.03

2.4E-13

16

57015091

rs5880

CETP

nsyn-exon

C

G

0.047

4049

−0.32

0.06

1.2E-8

16

57017319

rs1800777

CETP

nsyn-exon

A

G

0.029

3982

−0.40

0.07

8.1E-9

6

152679594

rs62426382

SYNE1

syn-exon

G

A

0.016

4035

0.45

0.09

1.6E-6

19

45396144

rs11556505

TOMM40

syn-exon

T

C

0.10

4018

−0.19

0.04

1.5E-6

19

45397229

rs1160983

TOMM40

syn-exon

A

G

0.02

2686

0.53

0.10

1.2E-7

11

116703640

rs5128

APOC3

UTR3

G

C

0.09

4003

−0.21

0.04

1.2E-7
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Fig. 2 Variant-wise association results on chromosome 10 around OBFC1 for telomere length phenotype (gray) and exceptional survival score
(green) on chromosome 10 using both 1000 Genomes Project hybrid and candidate gene sequenced genotypes. Two additional rare variants
from genome-wide array results showed significant association with survival exceptionality score. The association p-value of rs77987791 with
telomere length is 0.038

Factor 1 Receptor, located on chromosome 15q26.3) is
well known to be associated with cell growth and various
cancers [40]. As shown in Table 1, we noted one new
cancer associated rare UTR3 variant (chr15:99501295)
in this gene.
In addition, four genes (CETP, APOC3, SYNE1 and
TOMM40) were associated with blood lipid levels. The
cholesterol ester transfer protein, CETP (located on
chromosome 16q21), is essential for metabolism of plasma
lipoproteins [41]. Three known HDL cholesterol related
variants within CETP, one common intronic variant
(rs1532625) [42] and two rare exonic variants (rs5880,
rs1800777) [43], were replicated in our study. APOC3
(Apolipoprotein C3, located on chromosome 11q23.3) is
critical for triglyceride metabolism and a potential
therapeutic target for metabolic syndrome [44]. One
known common triglyceride related variant (rs5128)
[45] in the UTR3 region of APOC3 was replicated.
LDL cholesterol was associated with one synonymous
variant in SYNE1 (Spectrin Repeat Containing,
Nuclear Envelope 1, on chromosome 6q25.2) and two
synonymous variants in TOMM40 (Translocase Of
Outer Mitochondrial Membrane 40 Homolog, on
chromosome 19q13.32). TOMM40 has been identified
in genome-wide screens for dyslipidemia and carotid
artery disease [46, 47]. More importantly, TOMM40
rs10524523 polymorphism in combination with APOE
alleles significantly influences late-onset Alzheimer’s

disease and longevity [48]. Comparisons for all variants
listed in Table 2 between their associated phenotype and
the variant genotype are shown in Additional file 1: Figure
S2A-I.
Analyses of multiple variants across genes

To better characterize genes associated with our phenotypes due to multiple, pedigree-specific rare variants rather than more common single variants, we aggregated
rare functional variants (exonic, UTR3, UTR5, splicing
and non-coding RNA) within the same gene using the
PWST [25] and famSKAT [26]. For association results,
Bonferroni correction of 0.05 divided by the total number of genes resulted in a p < 1.14x10−4 for significance
and p < 1.0x10−3 would merely be suggestive. With respect to survival, none of the candidate genes passed this
significance threshold. When comparing our association
results for survival to published longevity related genes,
20 genes were replicated with p-value <0.05 (Additional
file 1: Table S8).
We next performed PWSK and famSKAT analyses on
our candidate genes to see if any gene harbored multiple putatively functional variants associated with the
individual Healthy Aging Index (HAI) and those results
are listed in Table 4. GSK3B (glycogen synthase kinase
3 beta, on chromosome 3q13.33) achieved significance
by PWSK. GSK3B, a serine-threonine kinase, has been
associated with Alzheimer’s disease [49, 50] and may
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Table 3 Significant results of single variant testing for variants with less than 10 copies. Twenty-three rare variants with less than
10 minor allele copies were identified for a single phenotype (longevity). These variants clustered in two families with high trait
exceptionality scores for longevity. Genes in bold have a previously published relationship to longevity [9, 29–34]
chr

Position (hg19)

7

17385235

11

27680107

16

57015065

1
8

rsID

gene

Function

Ref

Variant

Minor Allele Count

MAF

N

Beta

SE

P-value

AHR

UTR3

A

G

5

0.0006

810

3.58

0.71

6.18E-07

BDNF

nsyn-exonic

A

G

8

0.0009

810

5.02

1.01

7.41E-07

CETP

intronic

T

C

3

0.0004

809

5.00

1.01

8.69E-07

207813049

CR1

UTR3

A

G

5

0.0006

810

5.02

1.01

7.41E-07

6735377

DEFB1

nsyn-exonic

T

C

1

0.0001

809

5.03

1.01

7.22E-07

10

71139772

HK1

nsyn-exonic

T

C

1

0.0001

794

5.04

1.01

6.53E-07

1

209959231

IRF6

UTR3

G

A

4

0.0005

810

3.58

0.71

6.18E-07

21

35195906

ITSN1

syn-exonic

A

C

1

0.0001

810

5.02

1.01

7.41E-07

15

100256347

MEF2A

UTR3

C

T

2

0.0002

810

5.02

1.01

7.41E-07

1

12073445

MFN2

UTR3

T

C

3

0.0003

810

5.07

1.01

6.10E-07

4

100544175

MTTP

UTR3

G

A

1

0.0001

810

5.07

1.01

6.10E-07

2

1794502

MYT1L

UTR3

T

C

1

0.0001

810

5.02

1.01

7.41E-07

16

50267300

PAPD5

UTR3

T

C

4

0.0005

810

3.58

0.71

6.18E-07

2

223158616

PAX3

UTR3

T

C

3

0.0003

810

3.58

0.71

6.18E-07

7

95214257

PDK4

UTR3

G

A

2

0.0002

810

5.07

1.01

6.10E-07

5

149206403

PPARGC1B

syn-exonic

A

G

1

0.0001

714

5.07

1.00

4.72E-07

10

99130549

RRP12

nsyn-exonic

T

C

1

0.0001

780

5.02

1.01

7.66E-07

17

28525015

rs199875985

SLC6A4

UTR3

G

A

1

0.0001

810

5.07

1.01

6.10E-07

15

67479818

rs144245324

SMAD3

syn-exonic

T

C

3

0.0004

767

5.02

1.02

9.22E-07

3

24163883

THRB

UTR3

T

C

7

0.0008

810

3.58

0.71

6.18E-07

14

81610971

TSHR

UTR3

A

G

2

0.0002

810

5.07

1.01

6.10E-07

21

46189291

UBE2G2

UTR3

T

C

3

0.0004

810

5.02

1.01

7.41E-07

19

9770038

ZNF562

intronic

T

G

2

0.0002

810

3.58

0.71

6.18E-07

rs8192466

rs374853976

regulate human aging via negative regulation of glucose
homeostasis and Wnt signaling. In addition, NOTCH1
was significantly associated with diastolic blood pressure and TP53 with HDL (Table 4). NOTCH1 (chromosome 9q34.3) is involved in a variety of developmental
processes by controlling cell fate. In mice, NOTCH1
signaling is also required for vascular development
[51]. TP53 (tumor protein P53, located on chromosome
17p13.1), is a well known tumor suppressor that
regulates cell cycle and DNA repair. An inverse correlation of HDL cholesterol with cancer risk [52] might
be explained by the association of TP53 with HDL
cholesterol.
These results are likely an underestimate of significant
or suggestive variants. Unfortunately, non-uniform
hybridization to target loci due to local sequence context
and the need for stringent filtering to reduce false positives resulted in gaps within the covered coding sequence of most genes, which could affect results due to
false negatives. This is why the well-known longevity
gene, ApoE [53], was not included in our analyses.

Discussion
The mechanisms driving healthy human aging are still
mostly unclear. There is much debate on the evolutionary versus adaptive mechanisms of aging, such as programmed longevity, hormonal regulation of aging by
insulin/IGF-1 signaling, programmed decline of the immune system, wear and tear theory, rate of oxygen basal
metabolism, cross-linking theory and free radicals theory. These mechanisms are not inherently mutually
exclusive and it is likely that aging is dictated by combinations of multiple mechanisms. Regardless, Kirkwood and
Melev stated in a recent review that “it is obvious…that
duration of life is dependent upon genotype” [54].
To take advantage of the unique family structure of
the LLFS cohort, we have performed candidate gene
resequencing to identify familial sequence variation that
could explain multiple exceptional phenotypes contributing to long lifespan and healthy aging. Our results are
limited by gaps in sequencing coverage of some genes
due to non-uniform hybridization of baits across the entire cohort, which may mean an underestimate in the
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Fig. 3 Twenty-four rare variants within twenty-four genes clustered in two long-lived LLFS families (a) pedID 25609942 and (b) pedID 38652533.
Individual 2418 and 4441 lived to 110 and 101 years of age, respectively. The longevity-associated genes harboring rare variants within these
individuals (and their offspring) are listed below their symbol

number of familial variants in these genes. This strategy
was previously used to identify rare familial variants in
VEGFC (Vascular Endothelial Growth Factor C) by using
linkage information in families with high LOD scores to
inform targeted resequencing for rare variants. This

experiment identified a familial variant in VEGFC that
explained 23.8 % of phenotypic variance within a pedigree, but the same variant only described 0.1 % of the
phenotypic variance in unrelated individuals [55]. The
same strategy was employed in the Insulin Resistance

Table 4 Collapsed rare variant analysis of candidate genes associated with HAI. These genes were found to have a p-value <1.0x10−3 by
at least one burden-testing algorithm
Phenotype

Gene

RefSeq

Healthy Aging Index
(Mortality Weighted)

GSK3B

NM_002093 12

8

3217

77

121

1.00E-4

2.08E-4

Diastolic Blood Pressure NOTCH1 NM_017617 34

3

4112

55

78

1.00E-4

5.37E-3

HDL Cholesterol

6

4073

21

86

1.00E-4

8.05E-3

TP53

Total Exons Analyzed Exons Indiv Seq (#) Variants called (#) Ped (#) P-value (PWST) P-value (Skat)

NM_000546 11
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Atherosclerosis Family Study to identify a rare variant
within the ADIPOQ (Adiponectin, C1Q And Collagen
Domain Containing) gene describing 63 % of the variance of plasma adiponectin levels, which are critical for
glucose homeostasis [56]. Our results validate multiple
SNPs and genes (OBFC1, CTEP, ZNF562) found associated with longevity and healthy survival. Using a
sequencing-based approach to identify rare variants
within pedigrees associated with exceptional phenotypes. Of note, we identified one rare, novel variant in
OBFC1 as well as two intronic variants from LLFS array
data associated with survival. OBFC1 is involved in
telomere maintenance; its role in promoting exceptionally healthy aging is intriguing given that this gene resides squarely within a family-based association peak
for telomere length recently reported from the same
LLFS families [16]. The idea that many longevityassociated variants can presumably work in synergy
with an additive beneficial effect is supported by the
observations from three LLFS families. One exceptionally long-lived LLFS family carries all three OBFC1
variants, while 23 additional beneficial rare variants are
clustered in two other exceptionally long-lived LLFS
families.
Because effect sizes from single rare variants are typically small, collapsing rare variants across larger loci
(e.g. genes or pathways) can aggregate variants and
highlight the importance of a larger genetic locus [25].
By analyzing our sequencing results in this fashion, we
identified a more diverse set of genes associated (or
suggestive of association) with additional healthy aging
phenotypes. GSK3B, which is a kinase for over forty
different proteins and plays key roles in numerous
intracellular signaling pathways (cellular proliferation,
migration, inflammation and immune response, glucose regulation, and apoptosis) [57] was identified in
this analysis and may play an important role in healthy
aging. This gene has been associated with a number of
age-related diseases such as type II diabetes, Alzheimer’s
disease, inflammatory disorders, cancer and bipolar disorder [58].
Another healthy aging candidate gene, CETP, is a wellknown regulator of HDL and has been associated with
healthy aging in Ashkenazi Jewish [59, 60] as well as
Alzheimer’s disease [61]. The negative association of several variants with HDL, LDL and triglycerides in our
study indicates that harmful genetic variants still exist in
the long-lived subjects. This paradoxical phenomenon
might be due to antagonistic effects on the development
of other age-related disorders, gene-age, gene-gene, or
gene-environment interactions [62]. To understand
these intersections, further investigation of age and environment specific effects of these lipid regulatory genes
on multiple aging phenotypes is needed.
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Conclusions
Under the Rare Variant/Complex Phenotype hypothesis,
multiple rare variants have an aggregate effect on complex phenotypes or diseases, but identifying the genes
and the relative contributions of the various sequence
changes is difficult. By leveraging the pedigree structure
and cohort size of the LLFS study, we demonstrate the
utility of sequencing within pedigrees to identify inherited genetic variation influencing specific parameters of
healthy aging. These data are limited by representing
primarily genes that were already known to be associated with the various phenotypes being investigated. A
larger survey of the genome in the LLFS cohort, especially the linkage peaks for multiple healthy aging phenotypes, will facilitate discovery of new genes and
putative mechanisms for the genetic regulation of the
complexities of aging.
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